Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

Caroline Diorio; Elizabeth M. Anderson; Kevin O. McNerney; Eileen C. Goodwin; Julie C. Chase; Marcus J. Bolton; Claudia P. Arevalo; Madison E. Weirick; Sigrid Gouma; Laura A. Vella; Sarah E. Henrickson; Kathleen Chiotos; Julie C. Fitzgerald; Todd J. Kilbaugh; Audrey R.Odom John; Allison M. Blatz; Michele P. Lambert; Kathleen E. Sullivan; Margaret R. Tartaglione; Danielle Zambrano; Meghan Martin; Jessica H. Lee; Pampee Young; David Friedman; Deborah A. Sesok-Pizzini; Scott E. Hensley; Edward M. Behrens; Hamid Bassiri; David T. Teachey

doi:10.1002/pbc.28693

Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

Caroline Diorio
, Elizabeth M. Anderson
, Kevin O. McNerney
, Eileen C. Goodwin
, Julie C. Chase
, Marcus J. Bolton
, Claudia P. Arevalo
, Madison E. Weirick
, Sigrid Gouma
, Laura A. Vella
, Sarah E. Henrickson
, Kathleen Chiotos
, Julie C. Fitzgerald
, Todd J. Kilbaugh
, Audrey R.Odom John
, Allison M. Blatz
, Michele P. Lambert
, Kathleen E. Sullivan
, Margaret R. Tartaglione
, Danielle Zambrano

Meghan Martin, Jessica H. Lee, Pampee Young, David Friedman, Deborah A. Sesok-Pizzini, Scott E. Hensley, Edward M. Behrens, Hamid Bassiri, David T. Teachey

University of Pennsylvania
Holland Laboratory for Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.

Original language	English
Article number	e28693
Journal	Pediatric Blood and Cancer
Volume	67
Issue number	11
DOIs	https://doi.org/10.1002/pbc.28693
State	Published - 1 Nov 2020
Externally published	Yes

Keywords

convalescent plasma
COVID-19
pediatrics
SARS-CoV-2

Access to Document

10.1002/pbc.28693

Cite this

Diorio, C., Anderson, E. M., McNerney, K. O., Goodwin, E. C., Chase, J. C., Bolton, M. J., Arevalo, C. P., Weirick, M. E., Gouma, S., Vella, L. A., Henrickson, S. E., Chiotos, K., Fitzgerald, J. C., Kilbaugh, T. J., John, A. R. O., Blatz, A. M., Lambert, M. P., Sullivan, K. E., Tartaglione, M. R., ... Teachey, D. T. (2020). Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatric Blood and Cancer, 67(11), Article e28693. https://doi.org/10.1002/pbc.28693

@article{fd9e3f3489504680abc2b5fcbfb82eb7,

title = "Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome",

abstract = "There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.",

keywords = "convalescent plasma, COVID-19, pediatrics, SARS-CoV-2",

author = "Caroline Diorio and Anderson, \{Elizabeth M.\} and McNerney, \{Kevin O.\} and Goodwin, \{Eileen C.\} and Chase, \{Julie C.\} and Bolton, \{Marcus J.\} and Arevalo, \{Claudia P.\} and Weirick, \{Madison E.\} and Sigrid Gouma and Vella, \{Laura A.\} and Henrickson, \{Sarah E.\} and Kathleen Chiotos and Fitzgerald, \{Julie C.\} and Kilbaugh, \{Todd J.\} and John, \{Audrey R.Odom\} and Blatz, \{Allison M.\} and Lambert, \{Michele P.\} and Sullivan, \{Kathleen E.\} and Tartaglione, \{Margaret R.\} and Danielle Zambrano and Meghan Martin and Lee, \{Jessica H.\} and Pampee Young and David Friedman and Sesok-Pizzini, \{Deborah A.\} and Hensley, \{Scott E.\} and Behrens, \{Edward M.\} and Hamid Bassiri and Teachey, \{David T.\}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = nov,

day = "1",

doi = "10.1002/pbc.28693",

language = "English",

volume = "67",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

Diorio, C, Anderson, EM, McNerney, KO, Goodwin, EC, Chase, JC, Bolton, MJ, Arevalo, CP, Weirick, ME, Gouma, S, Vella, LA, Henrickson, SE, Chiotos, K, Fitzgerald, JC, Kilbaugh, TJ, John, ARO, Blatz, AM, Lambert, MP, Sullivan, KE, Tartaglione, MR, Zambrano, D, Martin, M, Lee, JH, Young, P, Friedman, D, Sesok-Pizzini, DA, Hensley, SE, Behrens, EM, Bassiri, H & Teachey, DT 2020, 'Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome', Pediatric Blood and Cancer, vol. 67, no. 11, e28693. https://doi.org/10.1002/pbc.28693

TY - JOUR

T1 - Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

AU - Diorio, Caroline

AU - Anderson, Elizabeth M.

AU - McNerney, Kevin O.

AU - Goodwin, Eileen C.

AU - Chase, Julie C.

AU - Bolton, Marcus J.

AU - Arevalo, Claudia P.

AU - Weirick, Madison E.

AU - Gouma, Sigrid

AU - Vella, Laura A.

AU - Henrickson, Sarah E.

AU - Chiotos, Kathleen

AU - Fitzgerald, Julie C.

AU - Kilbaugh, Todd J.

AU - John, Audrey R.Odom

AU - Blatz, Allison M.

AU - Lambert, Michele P.

AU - Sullivan, Kathleen E.

AU - Tartaglione, Margaret R.

AU - Zambrano, Danielle

AU - Martin, Meghan

AU - Lee, Jessica H.

AU - Young, Pampee

AU - Friedman, David

AU - Sesok-Pizzini, Deborah A.

AU - Hensley, Scott E.

AU - Behrens, Edward M.

AU - Bassiri, Hamid

AU - Teachey, David T.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.

AB - There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.

KW - convalescent plasma

KW - COVID-19

KW - pediatrics

KW - SARS-CoV-2

UR - https://www.scopus.com/pages/publications/85090117048

U2 - 10.1002/pbc.28693

DO - 10.1002/pbc.28693

M3 - Article

C2 - 32885904

AN - SCOPUS:85090117048

SN - 1545-5009

VL - 67

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

M1 - e28693

ER -

Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this